Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
28,172 people get JNJ articles and Market Currents by email alert.
Get email alerts on JNJ »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Johnson & Johnson's CEO Hosts Annual Meeting of Shareholders (Transcript)Thu, Apr 26, 2012 • 1 Comment
-
Johnson & Johnson Services, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Johnson & Johnson Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Johnson & Johnson Q4 2009 Earnings Call TranscriptTue, Jan 26, 2010
-
Johnson & Johnson Q3 2009 Earnings Call TranscriptTue, Oct 13, 2009
-
Johnson & Johnson Q2 2009 Earnings Call TranscriptTue, Jul 14, 2009
-
Johnson & Johnson F1Q09 (Qtr End 03/29/09) Earnings Call TranscriptTue, Apr 14, 2009 • 1 Comment
-
Johnson & Johnson Q4 2008 Earnings Call TranscriptTue, Jan 20, 2009
-
PR Newswire (Mon, 8:00AM)
-
at MarketWatch.com (Thu, 6:15AM)
-
PR Newswire (Wed, 9:00AM)
-
at CNBC.com (Jun 6, 2013)
-
at Fox Business (Jun 6, 2013)
-
at MarketWatch.com (Jun 6, 2013)
-
at CNBC.com (May 31, 2013)
-
at CNBC.com (May 29, 2013)
-
at CNBC.com (May 29, 2013)
-
at CNBC.com (May 29, 2013)
-
at CNBC.com (May 22, 2013)
-
at CNBC.com (May 20, 2013)
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 17, 2013)
-
at MarketWatch.com (May 17, 2013)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 14, 2013)
-
at MarketWatch.com (May 12, 2013)
-
at MarketWatch.com (May 3, 2013)
JNJ vs. ETF Alternatives
Company Description
General
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, November 15, 2012, 5:56 PM Johnson & Johnson (JNJ), Merck (MRK) and Eli Lilly (LLY) are collaborating in a global project to create a database aimed at getting patient tests of experimental drugs up and running more quickly and efficiently, which would eventually mean new medicines will get approved and reach patients sooner. The database will give drug companies working on experimental drugs a one-time approval process and drug makers a big pool of ready, qualified scientists with known expertise. Comment! [Healthcare]
- Wednesday, November 14, 2012, 8:16 PM Warren Buffett's Berkshire Hathaway discloses several changes to its portfolio, including a stake in Deere & Co. (DE) and selling off 5.3M shares of CVS Caremark (CVS). Firm also added to its existing investments in: Wells Fargo (WFC), Bank of New York Mellon Corp. (BK), General Motors (GM), DirecTV (DTV), DaVita (DVA), National Oilwell Varco (NOV) and Viacom (VIAB). It reduced stakes in: Johnson & Johnson (JNJ), Kraft Foods (KRFT), Lee Enterprises (LEE), Procter & Gamble (PG) and US Bancorp (USB). (13-F) 3 Comments [Financials]
- Friday, November 9, 2012, 5:16 PM Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV treatment for patients with no darunavir resistance-associated mutations. The drug is taken with ritonavir and in combination with other HIV medicines. Prezista is co-developed with Janssen Therapeutics, a division of JNJ owned Janssen Pharmaceutical. Comment! [Healthcare]
- Wednesday, November 7, 2012, 6:28 AM A fall in the short-term bond yields of Exxon Mobil (XOM) and Johnson & Johnson (JNJ) to below those of comparable Treasurys - a rare phenomenon caused by soaring demand as investors seek safety and a bit of return - is prompting some investors to predict that top-rated companies could soon be able to issue debt at cheaper rates than the government. "It's only a matter of time," says Carret's Jason Graybill. 1 Comment [U.S. Economy, Global & FX]
- Friday, November 2, 2012, 7:00 PM Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals says the FDA has approved Xarelto, an oral anticoagulant for the treatment of deep vein thrombosis and/or pulmonary embolism. The drug has a broad reimbursement base, encompassing more than 90% of commercial and Medicare health plan members. 2 Comments [Healthcare]
- Friday, November 2, 2012, 1:37 PM The FDA says it conducted an assessment of Johnson & Johnson (JNJ -0.2%) and Boehringer Ingelheim's Pradaxa using insurance claims and administrative data from its safety surveillance program, and found no evidence that the drug increased risk of bleeding when compared with warfarin. The agency launched an investigation of Pradaxa - which is approved to reduce the risk of stroke and embolism in patients with atrial fibrillation - last year after receiving reports of serious bleeding events in patients using the drug. 3 Comments [Healthcare]
- Monday, October 29, 2012, 1:52 PM Johnson & Johnson (JNJ) has recalled more than 157K surgical stapler devices and accessories used in hemorrhoid treatment procedures due to potential malfunctions that pose a serious safety risk. The FDA says use of the recalled devices could cause serious adverse health consequences, including death. The agency assigned its most serious classification, Class 1, to the recall last week. 7 Comments [Healthcare]
- Wednesday, October 17, 2012, 11:10 AM Johnson & Johnson (JNJ) declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.51%. For shareholders of record Nov 27. Payable Dec 11. Ex-div date Nov 23. (PR) Comment! [Dividends]
- Tuesday, October 16, 2012, 8:01 AM More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On a regional basis, gains in the Western Hemisphere and Asia-Pacific Africa helped to offset a 3.4% decline of revenue in Europe. Sees full-year 2012 EPS of $5.05-$5.10, lower than prior guidance of $5.00-$5.07 and the consensus mark of analysts calling for $5.06. Shares +1.2% premarket. (PR) 4 Comments [Consumer, Earnings]
- Tuesday, October 16, 2012, 7:49 AM Johnson & Johnson (JNJ): Q3 EPS of $1.25 beats by $0.04. Revenue of $17.1B (+6.5% Y/Y) beats by $150M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, October 16, 2012, 12:05 AM Notable earnings before Tuesday’s open: DPZ, FRX, GS, GWW, IRWD, JNJ, KO, MAT, OMC, PNC, STT, UNH Comment! [Earnings]
- Monday, October 15, 2012, 5:30 PM Notable earnings before Tuesday’s open: DPZ, FRX, GS, GWW, IRWD, JNJ, KO, MAT, OMC, PNC, STT, UNH Comment! [Earnings]
- Monday, October 15, 2012, 10:20 AM Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug for treating forms of leukemia or lymphoma and triggers a third $50M milestone payment from J&J (JNJ) unit Janssen Biotech. The company may receive up to an extra $675M in milestones, bringing total upfront and milestone payments to $975M. (PR) 1 Comment [Healthcare]
- Tuesday, October 9, 2012, 7:47 AM Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just 7% upside for the stock vs. double that for the rest of the pharmaceutical group (see Eli Lilly upgrade). "We see JNJ as lacking transformational pipeline opportunities." Shares -1.2% premarket. 1 Comment [Healthcare]
- Monday, October 8, 2012, 5:16 PM Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of its Doxil cancer drug. Under JNJ's plan, existing contract manufacturer Ben Venue Labs would produce Doxil while a second supplier would handle other tasks such as ensuring the drug is sterile. 1 Comment [Healthcare]
- Saturday, October 6, 2012, 8:15 AM Despite a Dividend 100 Index up 10% in 2012, dividend bargains are there to be had, especially if you look outside the U.S., Brett Arends suggests. And managers point to three attractive sectors in particular: pharmaceuticals, big energy and telecoms. Individual issues like JNJ, T, VZ and some global oil stocks look good, as well as ETFs like IDV, though it may be financials-heavy. Comment! [Quick Ideas, Energy, Healthcare]
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/25/2013 (Friday): (1-2-3) <c> <$JNJ $IBM $EDU> Johnson & Johnson ($JNJ) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/23/2013 (Wednesday): (2-3) ) <$JNJ $KSU> Johnson & Johnson ($JNJ) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
WhisperNumber
$JNJ earnings $1.19, 1 cent ahead of whisper number. Expected price reaction from today's open: http://seekingalpha.com/a/o2md - View all 0 replies
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/22/2013 (Tuesday): (1-2-3) Johnson & Johnson ($JNJ) Intuitive Surgical ($ISRG) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/14/2013 (Monday): (1-2-3) Johnson & Johnson ($JNJ) Coca Cola ($KO) Joy Global ($JOY) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 2 replies
-
O. Young Kwon: 1 = 1-m term. T (Topping): Leading Leaders (LDLD). A (Advancing): Lagging Leaders (LGLD), <c>
-
-
- View all 4 replies
-
RMF - Rethinking Modern Finance: just clarifying... are all these equities buys with their associated 1, 2, 3 months as periods for their price increase? -
O. Young Kwon: RMF. Yes, 1,2,3 indicate investment terms to expect a significant gains in one month, 2 months, and three months, respectively. yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (5/21/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: 2 = 2-month term. Momentum can help you (a) to manage your portfolios piecemeal, not on-off fashion,<c>
-
O. Young Kwon: and (b) to decide what securities (ETFs and Stocks) to buy, sell, or hold. yk
-
- View all 2 replies
-
O. Young Kwon: 1 = 1-m term. T (Topping): Leading Leaders (LDLD). A (Advancing): Lagging Leaders (LGLD), <c>
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/18/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
Tradevestor: Ya JNJ is going thru lots of issues. seen lots of JNJ investors complain on SA, so wanted to do this exercise
-
Tradevestor: You know what, interesting you talked about KMB, wrote a piece on how unappreciated KMB is http://seekingalpha.com/a/bm8f
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/17/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/16/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/15/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/14/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: 2 = 2-month term. Momentum can help you (a) to manage your portfolios piecemeal, not on-off fashion,<c>
-
O. Young Kwon: and (b) to decide what securities (ETFs and Stocks) to buy, sell, or hold. yk
-
- View all 2 replies
-
O. Young Kwon: 1 = 1-m term. T (Topping): Leading Leaders (LDLD). A (Advancing): Lagging Leaders (LGLD), <c>
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/11/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF TANER STOCK MOMENTUM (TM.S) (5/10/2012) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.